• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    More On COM.TO

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Cardiome Pharma Corp. (COM.TO)

    -Toronto
    5.54 Down 0.20(3.48%) Apr 29, 3:56PM EDT
    ProfileGet Profile for:
    Cardiome Pharma Corp.
    1441 Creekside Drive
    6th Floor
    Vancouver, BC V6J 4S7
    Canada - Map
    Phone: 604-677-6905
    Fax: 604-677-6915
    Website: http://www.cardiome.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients suffering from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; and develops TREVYENT for use in treating pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cardiome Pharma Corp.

    Key Executives 
     PayExercised
    Dr. William L. Hunter M.D., Msc, BSc, 53
    Chief Exec. Officer, Pres and Director
    1.17M0.00
    Ms. Jennifer Michael Archibald CA,
    Chief Financial Officer
    371.00K0.00
    Ms. Sheila M. Grant MBA,
    Chief Operating Officer
    295.00K0.00
    Mr. David D. McMasters Esq., J.D., 57
    Corp. Gen. Counsel
    320.00K0.00
    Mr. David Cameron Dean M.Sc,MBA,
    VP of Investor Relations and Bus. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.